OPEN END TURBO PUT WARRANT - GILEAD SCIENCES | Market Closed - Boerse Frankfurt Warrants 18:33:20 14/06/2024 BST | ||
| 2.4 EUR | -4.76% |
|
| Current month | -5.14% | ||
| 1 month | +9.59% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 2.4 | -4.76% |
| 13/06/24 | 2.52 | +2.86% |
| 12/06/24 | 2.45 | -0.41% |
| 11/06/24 | 2.46 | +0.41% |
| 10/06/24 | 2.45 | +1.24% |
Real-time Boerse Frankfurt Warrants
Last update June 14, 2024 at 06:33 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | UBS |
| WKN | UH4SQ1 |
| ISIN | DE000UH4SQ12 |
| Date issued | 03/12/2021 |
| Strike | 90.45 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.7 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.65 € |
|---|---|
| Lowest since issue | 0.32 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.06
USD
Average target price
82.7
USD
Spread / Average Target
+27.11%
- Stock Market
- Certificates
- Certificat
